Orserdu for ESR1-Mutated Advanced Breast Cancer

Orserdu is the brand name for elacestrant, an oral medicine used to treat certain hormone receptor-positive advanced or metastatic breast cancers with an ESR1 gene mutation. It is a targeted endocrine therapy prescribed after previous hormone-based treatment and requires ongoing care from an oncology team.

Orserdu at a glance

Orserdu is the brand name for elacestrant, a prescription medicine used in a specific setting of advanced breast cancer. It is an oral endocrine, or hormone-based, therapy. Unlike chemotherapy, endocrine therapies work by interfering with hormone signals that can support the growth of some breast cancer cells.

Orserdu is approved for postmenopausal women and adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer that has an ESR1 mutation. It is intended for people whose cancer has progressed after at least one previous line of endocrine therapy. Treatment choices are individualized, and an oncologist considers the cancer’s biology, prior therapies, symptoms, overall health, and personal preferences.

Advanced breast cancer means cancer that cannot be removed completely with surgery or has spread beyond the breast and nearby lymph nodes. This differs from early-stage breast cancer, where the main aim of treatment is usually cure. In advanced disease, treatment commonly focuses on controlling cancer, relieving symptoms, and preserving quality of life for as long as possible. More general information is available in the breast cancer overview.

How Orserdu works

Many breast cancers are ER-positive. In these cancers, estrogen can bind to estrogen receptors inside or on cancer cells and encourage cell growth. Orserdu belongs to a group of medicines called selective estrogen receptor degraders, or SERDs. It attaches to estrogen receptors and helps block estrogen-driven signaling while promoting degradation of the receptor.

This mechanism is especially relevant when a cancer has an ESR1 mutation. ESR1 is the gene that provides instructions for making the estrogen receptor. Certain mutations can allow the receptor to remain active even when estrogen levels are reduced by some other endocrine treatments. These mutations may develop as breast cancer adapts during treatment, particularly in metastatic disease.

Orserdu does not treat every type of breast cancer and is not appropriate simply because a tumor is hormone receptor-positive. HER2 status and ESR1 mutation status matter, as does the person’s treatment history. The prescribing oncologist will explain why a SERD is being considered and whether another endocrine therapy, targeted drug, chemotherapy, or another approach may be more suitable.

Who may be considered for treatment

Before Orserdu is prescribed, the cancer should be confirmed as ER-positive and HER2-negative, and testing should identify an ESR1 mutation. This testing may be performed on a tumor tissue sample or through a blood-based test that looks for tumor DNA circulating in the bloodstream. The oncology team selects an appropriate validated test and interprets the result in the context of the person’s medical history.

Orserdu is generally considered after cancer has grown or spread during or after prior endocrine therapy. Previous treatments may include medicines that lower estrogen levels, block estrogen receptors, or combine endocrine therapy with other targeted medicines. A past treatment response can help guide the next step, but it does not by itself determine whether Orserdu will work.

People should tell their cancer team about all health conditions, including liver problems, high cholesterol or triglycerides, and any history of difficulty swallowing tablets. The team also needs a complete list of prescription medicines, over-the-counter products, vitamins, and herbal supplements. This review supports safer treatment planning and may identify potential interactions.

Taking Orserdu safely

Orserdu is taken by mouth once daily with food, exactly as prescribed. Tablets should be swallowed whole and should not be chewed, crushed, or split. Taking the medicine at around the same time each day can make it easier to establish a routine. A pharmacist or oncology nurse can offer practical guidance if swallowing tablets is difficult.

If a dose is missed or vomiting occurs after a dose, people should follow the instructions given by their prescribing team and the medicine guide. In general, an extra dose should not be taken to make up for a missed dose unless a clinician specifically advises this. It is helpful to keep a record of doses and symptoms, particularly when starting a new treatment.

Some medicines can change the amount of elacestrant in the body. In particular, medicines and supplements that strongly or moderately affect the CYP3A4 enzyme system may require avoidance or a change in treatment plan. People should not start, stop, or alter any medicine, including herbal products, without asking their oncology team or pharmacist first. Grapefruit-related dietary questions should also be discussed with the prescriber.

Possible side effects and monitoring

Like all cancer medicines, Orserdu can cause side effects, although experiences vary. Commonly reported effects include nausea, tiredness, vomiting, reduced appetite, diarrhea or constipation, abdominal discomfort, headache, hot flushes, and muscle or joint aches. These symptoms may be manageable with supportive care, changes in daily routines, or medicines recommended by the care team.

Orserdu can also affect laboratory results, including cholesterol and triglyceride levels. The oncology team may arrange blood tests before treatment and during follow-up. They may also monitor liver-related test results, general well-being, weight, hydration, and how symptoms are affecting everyday activities. Results are assessed together rather than in isolation.

It is important to report side effects early rather than waiting for the next appointment. Persistent nausea, poor intake, diarrhea, or vomiting can lead to dehydration and may need treatment. The care team may recommend symptom-relief measures, temporary treatment adjustments, or further assessment. Patients should never reduce, pause, or discontinue Orserdu on their own unless instructed by their clinician.

Orserdu may harm a developing fetus. People who could become pregnant should discuss pregnancy testing and effective contraception with their oncology team before treatment and while taking the medicine. Breastfeeding considerations should also be discussed, since the clinician can provide individualized advice based on current prescribing guidance.

Treatment planning and daily life

Living with advanced breast cancer often involves regular scans, clinic visits, blood tests, and conversations about symptoms and goals of care. Imaging and clinical assessments help show whether treatment is controlling the cancer. A scan result is only one part of the picture; symptoms, physical examination, laboratory results, and treatment tolerability are also important.

Supportive care can be useful alongside anti-cancer treatment. This may include help with nausea, nutrition, fatigue, pain, emotional well-being, sleep, mobility, or menopausal symptoms. Gentle physical activity when appropriate, regular meals and fluids, and rest balanced with activity may help some people manage day-to-day effects. Recommendations should be adapted to the individual’s health, symptoms, and energy level.

Open communication is central to treatment planning. Patients may wish to bring a family member, caregiver, or written questions to appointments. Useful questions include what the treatment goal is, how response will be checked, which symptoms should be reported urgently, and what alternatives are available if the cancer progresses. Acibadem International’s multidisciplinary specialists and JCI-accredited hospitals diagnose and treat breast cancer for international patients.

When to seek medical care

Anyone taking Orserdu should contact their oncology team promptly for new, worsening, or persistent symptoms, especially repeated vomiting, inability to drink enough fluids, severe diarrhea, marked weakness, or side effects that interfere with normal daily activities. The team can advise whether symptoms can be managed at home, need a clinic review, or require urgent evaluation.

Urgent medical assessment is important for symptoms such as trouble breathing, chest pain, fainting, swelling of the face or throat, a severe rash, confusion, or signs of a serious allergic reaction. A fever or other possible signs of infection should also be discussed promptly with the cancer care team, as the appropriate response depends on the person’s treatment plan and overall condition.

New or rapidly worsening cancer-related symptoms should not be ignored. These can include escalating pain, new weakness or numbness, persistent severe headache, new vision changes, or a substantial change in bowel or bladder control. Such symptoms do not always indicate an emergency, but timely assessment helps clinicians identify the cause and provide appropriate care.

Frequently asked questions

Is Orserdu chemotherapy?

No. Orserdu is an endocrine therapy, also described as a targeted hormone therapy, rather than traditional chemotherapy. It works on estrogen receptors in certain breast cancer cells and is used only for a defined type of advanced breast cancer.

What is an ESR1 mutation?

An ESR1 mutation is a change in the gene involved in making the estrogen receptor. In some ER-positive breast cancers, this change can make the receptor active despite treatments that reduce estrogen. Testing for the mutation helps determine whether Orserdu may be an appropriate option.

How is ESR1 mutation testing performed?

Testing may be done using tumor tissue or a blood sample that detects cancer-derived DNA. The choice of test depends on available samples, the clinical situation, and local practice. An oncologist can explain what a result means and whether repeat testing is useful.

Can Orserdu be used for early-stage breast cancer?

Orserdu is used for ER-positive, HER2-negative advanced or metastatic breast cancer with an ESR1 mutation after previous endocrine treatment. It is not a routine treatment for early-stage breast cancer. Treatment for early-stage disease follows a different plan based on tumor features and recurrence risk.

What side effects should be reported to the oncology team?

Persistent nausea, vomiting, diarrhea, poor appetite, unusual tiredness, or symptoms that affect eating, drinking, or daily activities should be reported. The team should also know about new medications or supplements. Urgent symptoms, such as trouble breathing, chest pain, fainting, or swelling of the face or throat, require immediate medical assessment.

Can a person stop Orserdu if they feel better or develop side effects?

Orserdu should not be stopped or changed without guidance from the prescribing oncology team. Feeling better does not necessarily mean treatment is no longer needed, and side effects can often be assessed and managed. The clinician may recommend supportive care, monitoring, or a treatment adjustment when appropriate.

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.